Tolerability and safety outcomes of first-line oral second-generation antipsychotics in patients with schizophrenia.
Kristen M WardCitrome LesliePublished in: Expert opinion on drug safety (2024)
Among antipsychotics, there are many differences in adverse reactions observed in clinical trials, such as variable likelihood to cause sedation vs insomnia, weight gain and abnormalities in glucose/lipid metabolism, hyperprolactinemia, potential for impact on the QT interval, and motoric adverse effects. Additional safety data that can help with medication selection includes safety in pregnancy and lactation, and potential for drug-drug interactions. Ultimately, working with patients to personalize treatment by focusing on safety and individual tolerability considerations for various adverse effects can help in building a therapeutic alliance and improving patient outcomes.
Keyphrases
- weight gain
- clinical trial
- end stage renal disease
- body mass index
- chronic kidney disease
- ejection fraction
- newly diagnosed
- type diabetes
- healthcare
- big data
- peritoneal dialysis
- weight loss
- double blind
- adipose tissue
- pregnant women
- patient reported outcomes
- blood glucose
- depressive symptoms
- climate change
- study protocol